Prospective CiRculating prOstate Cancer Predictors in HighEr Risk mCRPC studY
Development of Circulating Molecular Predictors of Chemotherapy and Novel Hormonal Therapy Benefit in Men With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Sponsor: Dana-Farber Cancer Institute
Listed as NCT02269982, this observational or N/A phase trial focuses on Prostate Cancer and remains completed. Sponsored by Dana-Farber Cancer Institute, it has been updated 14 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
14 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Dec 2021 — Jul 2024 [monthly]
Completed
-
Jan 2021 — Dec 2021 [monthly]
Completed
-
Nov 2020 — Jan 2021 [monthly]
Completed
▶ Show 9 earlier versions
-
Jul 2019 — Nov 2020 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Mar 2019 — Jul 2019 [monthly]
Active Not Recruiting
-
Jun 2018 — Mar 2019 [monthly]
Active Not Recruiting
-
May 2018 — Jun 2018 [monthly]
Active Not Recruiting
-
Apr 2018 — May 2018 [monthly]
Active Not Recruiting
Phase: NA → None
-
Sep 2017 — Apr 2018 [monthly]
Active Not Recruiting NA
-
Aug 2017 — Sep 2017 [monthly]
Active Not Recruiting NA
-
Feb 2017 — Aug 2017 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Recruiting NA
First recorded
May 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Dana-Farber Cancer Institute
- Duke University
- Epic Sciences
- Johns Hopkins University
- Memorial Sloan Kettering Cancer Center
- Prostate Cancer Foundation
- Weill Medical College of Cornell University
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Baltimore, United States
- • Chicago, United States
- • Durham, United States
- • New York, United States